Amphastar Pharmaceuticals, Inc.
AMPH
$17.50
-$0.95-5.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 171.17M | 183.11M | 191.84M | 174.41M | 170.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 171.17M | 183.11M | 191.84M | 174.41M | 170.53M |
| Cost of Revenue | 100.85M | 97.44M | 93.19M | 87.92M | 85.28M |
| Gross Profit | 70.32M | 85.67M | 98.65M | 86.49M | 85.25M |
| SG&A Expenses | 29.96M | 26.75M | 27.87M | 24.23M | 27.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.54M | 147.50M | 143.42M | 132.23M | 133.24M |
| Operating Income | 13.63M | 35.61M | 48.42M | 42.18M | 37.29M |
| Income Before Tax | 10.05M | 31.91M | 21.51M | 39.34M | 30.86M |
| Income Tax Expenses | 3.63M | 7.49M | 4.16M | 8.31M | 5.58M |
| Earnings from Continuing Operations | 6.42M | 24.43M | 17.35M | 31.03M | 25.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.42M | 24.43M | 17.35M | 31.03M | 25.29M |
| EBIT | 13.63M | 35.61M | 48.42M | 42.18M | 37.29M |
| EBITDA | 27.98M | 49.95M | 62.55M | 56.80M | 50.90M |
| EPS Basic | 0.14 | 0.53 | 0.37 | 0.66 | 0.53 |
| Normalized Basic EPS | 0.14 | 0.43 | 0.60 | 0.52 | 0.40 |
| EPS Diluted | 0.14 | 0.51 | 0.37 | 0.64 | 0.51 |
| Normalized Diluted EPS | 0.14 | 0.42 | 0.58 | 0.51 | 0.39 |
| Average Basic Shares Outstanding | 45.32M | 45.91M | 46.47M | 46.95M | 47.64M |
| Average Diluted Shares Outstanding | 46.46M | 47.16M | 47.68M | 48.13M | 49.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |